Hotelbuchung
Hotel Registration
Grußwort
Welcome address
Beteiligte Gesellschaften
Societies involved
DOG Information
DOG Information
Eröffnung des Kongresses
Opening Ceremony
Preise
Awards
Ablauf der Tagung 2003
General overview of congress
Lageplan der Räumlichkeiten
Map of Congress Center
Wissenschaftliche Themen
Scientific topics
Symposien
Symposia
Wissenschaftliches Programm
Scientific program
Posterpräsentationen
Poster Presentation
Kurse
Courses
Begleitende Veranstaltungen
Accompanying program
Arbeitssitzungen
Working sessions
Rahmenprogramm
Social program
Allgemeine Informationen
General Information
Autorenindex
Index of Authors
Industrieaussteller
Commercial exhibitors
Sponsoren
Sponsors
Impressum
DOG Homepage
Abstract
Abstract
Ocular Toxoplasma Retinochorioiditis: Clinical Presentation, Treatment Response and Outcome
Lie A., Callizo J., Metzner S., Hartmann C., Torun N., Pleyer U.
Dept. of Ophthalmology, Charité, Campus Virchow Hospital, Humboldt University of Berlin
Purpose: To present the clinical characteristics, diagnostic measures and treatment outcome in toxoplasma retinochorioiditis.
Method: In a consecutive series of 996 uveitis patients we identified 104 individuals with active ocular toxoplasmosis. All patients underwent a standard diagnostic protocol and if indicated, additional diagnostic tests such as aqueous humor analysis (n=74 patients). Data were analysed regarding clinical characteristics, presentation of ocular manifestation and treatment response following a standardized therapeutic approach. In addition, a subgroup of patients with central retinochoroidal lesions was followed by sequential visual field testing (n=24).
Results: All patients presented with an active toxoplasma retinochorioiditis of whom 47 (45%) had a recurrent manifestation. The mean age at onset of new or recurrent inflammatory lesions was 34 years. Our standardized initial treatment approach consisting of Clindamycin (4x600mg) was generally well tolerated but led to adverse effects in 7 patients (6.7%). Temporary applied Corticosteroids were necessary in 75 patients (73%) to control vitreous inflammation. In only 4 patients (3.8%) a combined treatment with Clindamycin/Pyremethamine had to be instilled because of unsatisfactory treatment response to monotherapy. Within a treatment period of 6.8